1
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W,
Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized,
prospective trial of the addition of ifosfamide and/or muramyl
tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J
Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bacci G, Forni C, Longhi A, Ferrari S,
Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A and Picci
P: Local recurrence and local control of non-metastatic
osteosarcoma of the extremities: A 27-year experience in a single
institution. J Surg Oncol. 96:118–123. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Jawad MU, Cheung MC, Clarke J, Koniaris LG
and Scully SP: Osteosarcoma: Improvement in survival limited to
high-grade patients only. J Cancer Res Clin Oncol. 137:597–607.
2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ohata N, Ito S, Yoshida A, Kunisada T,
Numoto K, Jitsumori Y, Kanzaki H, Ozaki T, Shimizu K and Ouchida M:
Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma:
Involvement of cyclin C in osteosarcoma. Int J Mol Med.
18:1153–1158. 2006.PubMed/NCBI
|
5
|
Mialou V, Philip T, Kalifa C, Perol D,
Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles
AS and Hartmann O: Metastatic osteosarcoma at diagnosis: Prognostic
factors and long-term outcome - the French pediatric experience.
Cancer. 104:1100–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, Csoka M and Kovacs G: Good prognosis of localized
osteosarcoma in young patients treated with limb-salvage surgery
and chemotherapy. Pediatr Blood Cancer. 57:415–422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Stokkel MP, Linthorst MF, Borm JJ,
Taminiau AH and Pauwels EK: A reassessment of bone scintigraphy and
commonly tested pretreatment biochemical parameters in newly
diagnosed osteosarcoma. J Cancer Res Clin Oncol. 128:393–399. 2002.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Bartkova J, Horejsí Z, Koed K, Krämer A,
Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et
al: DNA damage response as a candidate anti-cancer barrier in early
human tumorigenesis. Nature. 434:864–870. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wu L and Hickson ID: DNA helicases
required for homologous recombination and repair of damaged
replication forks. Annu Rev Genet. 40:279–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Takata K, Reh S, Tomida J, Person MD and
Wood RD: Human DNA helicase HELQ participates in DNA interstrand
crosslink tolerance with ATR and RAD51 paralogs. Nat Commun.
4:23382013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tafel AA, Wu L and McHugh PJ: Human HEL308
localizes to damaged replication forks and unwinds lagging strand
structures. J Biol Chem. 286:15832–15840. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Adelman CA, Lolo RL, Birkbak NJ, Murina O,
Matsuzaki K, Horejsi Z, Parmar K, Borel V, Skehel JM, Stamp G, et
al: HELQ promotes RAD51 paralogue-dependent repair to avert germ
cell loss and tumorigenesis. Nature. 502:381–384. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Stolk L, Perry JR, Chasman DI, He C,
Mangino M, Sulem P, Barbalic M, Broer L, Byrne EM, Ernst F, et al:
LifeLines Cohort Study: Meta-analyses identify 13 loci associated
with age at menopause and highlight DNA repair and immune pathways.
Nat Genet. 44:260–268. 2012. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Krajewska M, Fehrmann RS, Schoonen PM,
Labib S, de Vries EG, Franke L and van Vugt MA: ATR inhibition
preferentially targets homologous recombination-deficient tumor
cells. Oncogene. 34:3474–3481. 2015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Jia Y, Song W, Zhang F, Yan J and Yang Q:
Akt1 inhibits homologous recombination in Brca1-deficient cells by
blocking the Chk1-Rad51 pathway. Oncogene. 32:1943–1949. 2013.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Ward JD, Muzzini DM, Petalcorin MI,
Martinez-Perez E, Martin JS, Plevani P, Cassata G, Marini F and
Boulton SJ: Overlapping mechanisms promote postsynaptic RAD-51
filament disassembly during meiotic double-strand break repair. Mol
Cell. 37:259–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Neri M, Milazzo D, Ugolini D, Milic M,
Campolongo A, Pasqualetti P and Bonassi S: Worldwide interest in
the comet assay: A bibliometric study. Mutagenesis. 30:155–163.
2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ashby J, Tinwell H, Lefevre PA and Browne
MA: The single cell gel electrophoresis assay for induced DNA
damage (comet assay): Measurement of tail length and moment.
Mutagenesis. 10:85–90. 1995. View Article : Google Scholar : PubMed/NCBI
|
20
|
Lu HF, Lai TY, Hsia TC, Tang YJ, Yang JS,
Chiang JH, Lu CC, Liu CM, Wang HL and Chung JG: Danthron induces
DNA damage and inhibits DNA repair gene expressions in GBM 8401
human brain glioblastoma multiforms cells. Neurochem Res.
35:1105–1110. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Woodman IL and Bolt EL: Molecular biology
of Hel308 helicase in archaea. Biochem Soc Trans. 37:74–78. 2009.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Marini F and Wood RD: A human DNA helicase
homologous to the DNA cross-link sensitivity protein Mus308. J Biol
Chem. 277:8716–8723. 2002. View Article : Google Scholar : PubMed/NCBI
|
23
|
Muzzini DM, Plevani P, Boulton SJ, Cassata
G and Marini F: Caenorhabditis elegans POLQ-1 and HEL-308 function
in two distinct DNA interstrand cross-link repair pathways. DNA
Repair (Amst). 7:941–950. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Guy CP and Bolt EL: Archaeal Hel308
helicase targets replication forks in vivo and in vitro and unwinds
lagging strands. Nucleic Acids Res. 33:3678–3690. 2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Li WQ, Hu N, Hyland PL, Gao Y, Wang ZM, Yu
K, Su H, Wang CY, Wang LM, Chanock SJ, et al: Genetic variants in
DNA repair pathway genes and risk of esophageal squamous cell
carcinoma and gastric adenocarcinoma in a Chinese population.
Carcinogenesis. 34:1536–1542. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Gao Y, He Y, Xu J, Xu L, Du J, Zhu C, Gu
H, Ma H, Hu Z, Jin G, et al: Genetic variants at 4q21, 4q23 and
12q24 are associated with esophageal squamous cell carcinoma risk
in a Chinese population. Hum Genet. 132:649–656. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Liang C, Marsit CJ, Houseman EA, Butler R,
Nelson HH, McClean MD and Kelsey KT: Gene-environment interactions
of novel variants associated with head and neck cancer. Head Neck.
34:1111–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
28
|
McKay JD, Truong T, Gaborieau V, Chabrier
A, Chuang SC, Byrnes G, Zaridze D, Shangina O, Szeszenia-Dabrowska
N, Lissowska J, et al: A genome-wide association study of upper
aerodigestive tract cancers conducted within the INHANCE
consortium. PLoS Genet. 7:e10013332011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Montano R, Thompson R, Chung I, Hou H,
Khan N and Eastman A: Sensitization of human cancer cells to
gemcitabine by the Chk1 inhibitor MK-8776: Cell cycle perturbation
and impact of administration schedule in vitro and in vivo. BMC
Cancer. 13:6042013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Bourke E, Dodson H, Merdes A, Cuffe L,
Zachos G, Walker M, Gillespie D and Morrison CG: DNA damage induces
Chk1-dependent centrosome amplification. EMBO Rep. 8:603–609. 2007.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Parplys AC, Seelbach JI, Becker S, Behr M,
Wrona A, Jend C, Mansour WY, Joosse SA, Stuerzbecher HW, Pospiech
H, et al: High levels of RAD51 perturb DNA replication elongation
and cause unscheduled origin firing due to impaired CHK1
activation. Cell Cycle. 14:3190–3202. 2015. View Article : Google Scholar : PubMed/NCBI
|